Startups
Graviton Bioscience
New York, New York, United States
New York biotechnology company developing selective ROCK2 inhibitors and other therapeutics for central nervous system, autoimmune, fibrotic and metabolic disorders. Founded in 2020 by Samuel Waksal. Its GV101 program received FDA IND clearance for Friedreich’s ataxia in August 2026, with a Phase 2 study planned to begin enrollment in the first quarter of 2027. Its broader published pipeline includes progressive multiple sclerosis, ALS and Alzheimer’s disease alongside non-neurological indications. The earlier Ovid collaboration for OV888/GV101 in rare CNS disorders was paused by Ovid in late 2024, according to its 2025 annual report; the Graviton website’s older collaboration description does not establish an active Phase 2 trial. Backers include Enavate Sciences, Cormorant, Pontifax, Ovid and Sanofi. No company AI platform has been verified.
Founded 2020
Team
 Alexandra Zanin-ZhorovSenior Vice President, Translational Medicine |
 Amy MelsaetherSenior Vice President, Chief Medical Officer |
 David MacMillanBoard Member |
 Dixon BoardmanBoard Member |
 James BoylanBoard Member |
 Jean (Ji-In) KimSenior Vice President, Head of Chemistry |
 Justin StebbingSenior Vice President, Clinical & Scientific Strategy |
 Michael WigotskySenior Vice President, General Counsel and Head of Compliance |
 Ran NussbaumChairman |
 Rui WuExecutive Vice President, Head of Research and Preclinical & Chief CMC Officer |
 Samia ShamimSenior Vice President, Business Development & Chief of Staff |
 Samuel WaksalFounder & Chief Executive Officer · Board Member |